Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?: The Time to Act Is Now
- PMID: 33617314
- DOI: 10.1161/CIRCULATIONAHA.120.053058
Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?: The Time to Act Is Now
Keywords: Editorials; glucagon-like peptide receptors; sodium-glucose transporter 2 inhibitors.
Comment on
-
Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.Circulation. 2021 Feb 23;143(8):770-779. doi: 10.1161/CIRCULATIONAHA.120.047965. Epub 2020 Dec 11. Circulation. 2021. PMID: 33302723 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
